Sugi Predict

Sugi Predict / Compounds / SCHEMBL5543211

SCHEMBL5543211

SCHEMBL5543211

Cc1cc2[nH]c(=O)oc2cc1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOS1 P29475 5/20 0.53
▸ NOS2 P35228 4/20 0.53
▸ NOS3 P29474 3/20 0.53
▸ KMO O15229 1/20 0.52
▸ TSHR P16473 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ ADRA2A P08913 1/20 0.44
▸ THPO P40225 1/20 0.44
▸ BLM P54132 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ OGT O15294 1/20 0.41
▸ CREBBP Q92793 1/20 0.41
▸ PDE3B Q13370 2/20 0.39
▸ PDE3A Q14432 2/20 0.39
▸ POLB P06746 2/20 0.39
▸ ALPL P05186 1/20 0.39
▸ ALPI P09923 1/20 0.39
▸ ALPG P10696 1/20 0.39
▸ MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30881282 0.93 NOS1 (0.53) NOS1NOS2NOS3KMOTSHR
SCHEMBL5539700 0.93 NOS1 (0.53) NOS1NOS2NOS3KMOTSHR
SCHEMBL17069084 0.84 NOS1 (0.60) NOS1NOS2NOS3KMOTSHR
SCHEMBL522196 0.81 NOS1 (0.53) NOS1NOS2NOS3KMOTSHR
SCHEMBL5536562 0.78 NOS1 (0.53) NOS1NOS2NOS3KMOTSHR
SCHEMBL4297310 0.78 KMO (0.52) NOS1NOS2NOS3KMOTSHR
SCHEMBL5542896 0.78 KMO (0.72) NOS1NOS2NOS3KMOTSHR
Bromchlorenone SCHEMBL637478 0.78 KMO (0.72) NOS1NOS2NOS3KMOTSHR
SCHEMBL11040016 0.78 NOS1 (0.53) NOS1NOS2NOS3KMOTSHR
SCHEMBL5543204 0.78 KMO (0.52) NOS1NOS2NOS3KMOTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF SIRONAX LTD (KY) 2026-03-19 — — US disclosed
EP-4590674-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2025-07-30 — — EP disclosed
CN-114853730-B Compounds used as HPK1 kinase inhibitor, preparation method and application thereof 中国药科大学 2024-03-26 — — CN disclosed
EP-3601284-B1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 HOFFMANN LA ROCHE (CH) 2023-12-27 — — EP disclosed
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-08-24 — — US disclosed
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEONE MEDICINES I GMBH (CH) 2023-08-24 — — US disclosed
CN-116323580-A Conjugated degradation (EGFR) of EGFR inhibitors to E3 ligase ligands and methods of use 百济神州有限公司 2023-06-23 — — CN disclosed
CN-110678466-B Diazanaphthalenes as HPK1 inhibitors 豪夫迈·罗氏有限公司 2023-01-31 — — CN disclosed
CN-114853730-A Compound used as HPK1 kinase inhibitor and preparation method and application thereof 中国药科大学 2022-08-05 — — CN disclosed
WO-2022012622-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE, LTD. (KY) 2022-01-20 — — WO disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 — — EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 — — EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 — — US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 — — US disclosed
EP-1286975-B1 BICLYCLIC CYCLOHEXYLAMINES AND THEIR USE AS NMDA RECEPTOR ANTAGONISTS WARNER LAMBERT CO (US) 2005-08-24 — — EP disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 — — EP disclosed
US-6794402-B2 Bicyclic cyclohexylamines and their use as NMDA receptor antagonists WARNER-LAMBERT COMPANY 2004-09-21 — — US disclosed
US-20030236252-A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists NIKAM SHAM SHRIDHAR (US) 2003-12-25 — — US disclosed
EP-1286975-A1 BICLYCLIC CYCLOHEXYLAMINES AND THEIR USE AS NMDA RECEPTOR ANTAGONISTS WARNER-LAMBERT COMPANY (US) 2003-03-05 — — EP disclosed
WO-2001092239-A1 BICICLIC CYCLOHEXYLAMINES AND THEIR USE AS NMDA RECEPTOR ANTOGONISTS WARNER-LAMBERT COMPANY (US) 2001-12-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265116-A1 DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE EGFR, CBL, ERBB2 NOS1 4567/4885NOS2 4652/4885NOS3 4600/4885
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NOS1 553/4885NOS2 610/4885NOS3 214/4885
US-20260078130-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF NAMPT, NNMT, SARM1 NOS1 2579/4885NOS2 3492/4885NOS3 2690/4885
US-20030236252-A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists GRIN1, GRIN2C, GRIN2A NOS1 1914/4885NOS2 2566/4885NOS3 2585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.